Genmab — Juli 2018
-
Seattle Genetics (SGEN) Q2 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4190986-seattle-genetics-sgen-q2-2018-results-earnings-call-transcript?part=single
-
Our third late-stage program is tisotumab vedotin. which we're developing with Genmab. We've achieved two recent milestones. We've dosed the first patient in a pivotal trial for women with recurrent or metastatic cervical cancer. And we started a Phase 2 basket trial evaluating tisotumab vedotin in other solid tumors. These trials are intended to support an initial accelerated approval pathway in cervical cancer and inform opportunities to broaden the program.
-
Our third late-stage clinical program in our pipeline is tisotumab vedotin, or TV, which we are co-developing with Genmab. We recently treated the first patient with TV in the pivotal Phase 2 single-arm monotherapy trial called innovaTV 204 in women with second or third line cervical cancer. Target enrollment is approximately 100 patients and the primary endpoint is ORR. The trial is intended to support regulatory submission under the FDA's accelerated approval pathway
-
We and Genmab are also planning a trial of TV in combination with other agents with a goal of understanding TV's potential in earlier lines of cervical cancer. This study will likely start in 2019, initially in the second line setting with the goal of moving into first line. Lastly, another recent accomplishment with the TV program is that we treated the first patient in a Phase 2 basket trial.
-
This trial is enrolling four solid tumor types that highly expressed tissue factor including pancreatic, head and neck, colorectal, and head and neck, colorectal and non-small cell lung cancer. This study is designed to inform a potentially expanded development program of TV.
-
and of interest on ADC:
Our ADC collaborators are also making substantial progress with programs using our technology, underscoring the growing importance of ADCs in the treatment of cancer. An example of this was yesterday during the GSK Q2 results and R&D update where they highlighted their BCMA ADC in multiple myeloma, which utilizes our technology. GSK presented a broad development strategy, including several pivotal trials with this ADC as monotherapy and in combination regimens. -
De anonyme for solgt godt her fra morgenen. Mon de har opsnuset noget inden markedet?
-
Får
-
Hvis det er tommel ned, så ville vi nok se en noget mere dramatisk volumen
-
efter luk
-
JV> Dagen er jo ikke slut endnu. Håber dog du har ret.
-
Dagen inden solide tumorer failede, så vi samme mønster. Der tog salget til om eftermiddagen.
-
der var denne dag offentliggjort en negativ Azerra nyhed, så kan ikke sammenlignes
-
NN går også ned - mon ikke blot det er en lille smule svær dag for biotek. Det er jo set mange gange før.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind